Q0144 HCPCS code: Azithromycin dihydrate, oral, capsules/powder, 1 gram
Q0144 is the HCPCS Level II code for azithromycin dihydrate, oral, capsules/powder, 1 gram. Its Medicare coverage code is M (Non-covered by Medicare): Medicare does not cover this item or service.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | M — Non-covered by Medicare |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | O1E — Other drugs |
| Added | 1996-07-01 |
| Last action effective | 2002-07-01 |
What changed for Q0144
- 1996-07-01: Q0144 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q0144?
Q0144 is the HCPCS Level II code for azithromycin dihydrate, oral, capsules/powder, 1 gram. Short descriptor: "Azithromycin dihydrate, oral".
Does Medicare cover Q0144?
Coverage code M — Non-covered by Medicare. Medicare does not cover this item or service.
Related Q01 codes
- Q0111 — Wet mounts, including preparations of vaginal, cervical or skin specimens
- Q0112 — All potassium hydroxide (koh) preparations
- Q0113 — Pinworm examinations
- Q0114 — Fern test
- Q0115 — Post-coital direct, qualitative examinations of vaginal or cervical mucous
- Q0138 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
- Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
- Q0155 — Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0161 — Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
- Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q0144
- Watch Q0144 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q0144
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.